We are live on ! Find out more
DMK

David M. Knott Portfolio holdings

AUM $275M Turnover 23.21%
1-Year Est. Return 59.23%
This Fund
S&P 500
This Quarter Est. Return
+17.17%
1 Year Est. Return
+59.23%
3 Year Est. Return
+80.95%
5 Year Est. Return
+223.18%
10 Year Est. Return
–
AUM
$234M
AUM Growth
+$12.8M
Cap. Flow
-$28.9M
Cap. Flow %
-12.38%
Top 10 Hldgs %
47.79%
Holding
149
New
39
Increased
14
Reduced
25
Closed
20
Avg Time Held
2.5 years
Top 10 Avg Time Held
1.9 years
Top 20 Avg Time Held
1.6 years

Top Buys

Rank Stock Value
1
AGAC.U
African Gold Acquisition Corp Units
AGAC.U
+$6.16M
2
TWLVU icon
Twelve Seas Investment Company II Unit
TWLVU
+$5.13M
3
GLHAU
Glass Houses Acquisition Corp. Unit
GLHAU
+$5M
4
LOKM.U
Live Oak Mobility Acquisition Corp. Units, each consisting of one share of Class A common stock, and one-fifth of one warrant
LOKM.U
+$3.67M
5
KAIR
Kairos Acquisition Corp. Class A Ordinary Shares
KAIR
+$2.56M

Top Sells

Rank Stock Value
1
LGND icon
Ligand Pharmaceuticals
LGND
+$26.2M
2
DNMR icon
Danimer Scientific, Inc.
DNMR
+$12.2M
3
FTAI icon
FTAI Aviation
FTAI
+$5.24M
4
UPLD icon
Upland Software
UPLD
+$5.14M
5
LKQ icon
LKQ Corp
LKQ
+$4.23M

Sector Composition

Rank Sector Weight
1 Healthcare 28.38%
2 Financials 22.64%
3 Miscellaneous 13.12%
4 Materials 11.65%
5 Technology 6.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
TGTX icon
26
TG Therapeutics
TGTX
$8.26B
$2.5M 1.07%
51,973
+1,200
+2% +$57.7K
2020 Q2
3 quarters
AVDL
27
DELISTED
Avadel Pharmaceuticals
AVDL
$2.47M 1.06%
272,845
+185,929
+214% +$1.5M
2020 Q4
1 quarter
EIGR
28
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$2.45M 1.05%
9,218
-617
-6% -$194K
2017 Q3
14 quarters
UTHR icon
29
United Therapeutics
UTHR
$22.9B
$2.42M 1.04%
+14,500
New +$2.42M
2021 Q1
0 quarters
JPM icon
30
JPMorgan Chase
JPM
$902B
$2.36M 1.01%
15,470
-4,500
-23% -$647K
2013 Q2
31 quarters
ZGNX
31
DELISTED
Zogenix, Inc.
ZGNX
$2.3M 0.98%
117,688
+4,981
+4% +$102K
2020 Q1
4 quarters
TRIL
32
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.13M 0.91%
198,699
+24,000
+14% +$297K
2020 Q1
4 quarters
HZAC
33
DELISTED
Horizon Acquisition Corporation
HZAC
$2.08M 0.89%
210,100
– –
2020 Q4
1 quarter
AB icon
34
AllianceBernstein
AB
$3.21B
$2.02M 0.86%
50,500
– –
2013 Q2
31 quarters
AUPH icon
35
Aurinia Pharmaceuticals
AUPH
$2.2B
$2.01M 0.86%
154,840
-22,700
-13% -$329K
2020 Q1
4 quarters
CNST
36
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$2.01M 0.86%
85,909
+52,909
+160% +$1.6M
2020 Q4
1 quarter
MSACU
37
DELISTED
Medicus Sciences Acquisition Corp. Unit
MSACU
$1.97M 0.84%
+200,000
New +$2.03M
2021 Q1
0 quarters
PMGM icon
38
DELISTED
Priveterra Acquisition Corp. II Class A Common Stock
PMGM
$1.95M 0.83%
+200,000
New +$1.96M
2021 Q1
0 quarters
BRPMU
39
DELISTED
B. Riley Principal 150 Merger Corp. Unit
BRPMU
$1.76M 0.75%
+175,963
New +$1.79M
2021 Q1
0 quarters
BRSL icon
40
Brightstar Lottery PLC
BRSL
$1.74B
$1.72M 0.74%
107,500
– –
2019 Q1
8 quarters
KAIRW
41
DELISTED
Kairos Acquisition Corp. Warrant
KAIRW
$1.5M 0.64%
+130,687
New +$108K
2021 Q1
0 quarters
ASLN
42
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$1.46M 0.63%
+10,935
New +$1.39M
2021 Q1
0 quarters
CHRS icon
43
Coherus Oncology
CHRS
$153M
$1.46M 0.62%
99,655
-2,000
-2% -$34K
2017 Q2
15 quarters
QURE icon
44
uniQure
QURE
$1.51B
$1.41M 0.6%
41,766
+6,766
+19% +$242K
2019 Q4
5 quarters
VKTX icon
45
Viking Therapeutics
VKTX
$3.2B
$1.32M 0.56%
208,102
-10,000
-5% -$70.4K
2017 Q4
13 quarters
VRCA icon
46
Verrica Pharmaceuticals
VRCA
$61.8M
$1.19M 0.51%
7,842
+183
+2% +$25.3K
2019 Q2
7 quarters
PMGMW icon
47
DELISTED
Priveterra Acquisition Corp. II Warrant to purchase Class A common stock
PMGMW
$1.15M 0.49%
+100,000
New +$73.6K
2021 Q1
0 quarters
CDTX icon
48
DELISTED
Cidara Therapeutics
CDTX
$1.1M 0.47%
20,765
– –
2019 Q2
7 quarters
VZ icon
49
Verizon
VZ
$186B
$1.03M 0.44%
17,711
-600
-3% -$33.9K
2014 Q2
27 quarters
ROCRU
50
DELISTED
Roth CH Acquisition III Co. Unit
ROCRU
$1M 0.43%
+100,000
New +$1M
2021 Q1
0 quarters
1
2
3 4 5

Similar funds

FA
FMA Advisory Harrisburg, Pennsylvania $268M AUM 30.8% 1-Year Est. Return
KCP
KDI Capital Partners Raleigh, North Carolina $290M AUM 26.07% 1-Year Est. Return
HCIA
Hochman Cole Investment Advisors Deerfield, Illinois $255M AUM 23.27% 1-Year Est. Return
ISG
Investment Security Group Denver, Colorado $252M AUM 28.26% 1-Year Est. Return
TPCM
Three Peaks Capital Management Castle Rock, Colorado $301M AUM 43.39% 1-Year Est. Return
DCM
DeGreen Capital Management Scottsdale, Arizona $301M AUM 17.24% 1-Year Est. Return
MCL
MIK Capital LP New York $247M AUM 78.02% 1-Year Est. Return
DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return

David M. Knott's Q1 2021 Portfolio in Review

As of Q1 2021, David M. Knott held 149 positions worth $234M, up 5.8% from $221M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

David M. Knott withdrew a net $28.9M in Q1 2021, closing 20 positions and reducing 25 holdings. Its most notable exit was LKQ Corp, an estimated $4.23M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 28% of assets, down from 36% a quarter earlier, followed by Financials and Miscellaneous.

Against the trend, David M. Knott opened a new position in African Gold Acquisition Corp Units worth $6.11M.

  • David M. Knott's largest Q1 2021 buy was African Gold Acquisition Corp Units: 618,000 shares worth $6.11M.
  • David M. Knott added most to Constellation Pharmaceuticals, Inc. in Q1 2021, an estimated $1.6M increase.
  • David M. Knott's biggest Q1 2021 reduction was Ligand Pharmaceuticals, cutting an estimated $26.2M.
  • David M. Knott fully exited LKQ Corp in Q1 2021, selling an estimated $4.23M.
  • David M. Knott's ten largest holdings make up 48% of its $234M portfolio in Q1 2021.
  • David M. Knott opened 39 new positions and closed 20 in Q1 2021.
  • David M. Knott's portfolio value rose 5.8% quarter-over-quarter to $234M.

Based on David M. Knott's 13F filing for Q1 2021, filed 13 May 2021.